James Paul Rickey - 05 Aug 2026 Form 4 Insider Report for Braveheart Bio, Inc. (BRVE)

Reporting relationship: Chief Financial Officer
Issuer ticker: BRVE
Reported as of: 05 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2026, 16:41:40 UTC
Prior SEC filing: 20 May 2024
Source filing: View source filing
Reporting owner signature: /s/ James Paul Rickey

Key filing fact

James Paul Rickey filed Form 4 for Braveheart Bio, Inc. (BRVE) on 07 Aug 2026.

Key facts

This page summarizes James Paul Rickey's Form 4 filing for Braveheart Bio, Inc. (BRVE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Aug 2026, 16:41.

Change

Previous filing in this sequence was filed on 20 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001606243 Primary reporting owner

Rickey James Paul

Relationship: Chief Financial Officer
Address: C/O BRAVEHEART BIO, INC., ONE LETTERMAN DR., BLDG. A, SUITE A4-300, SAN FRANCISCO
Signature: /s/ James Paul Rickey
Signature date: 07 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BRVE transaction

Common Stock

Purchase

Transaction value
Shares: +27,777
Change %: +5.6%
Price: $18.00^*
Shares after: 520,927
Date: 07 Aug 2026
Ownership: Direct

BRVE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 91,324
Date: 05 Aug 2026
Ownership: By Rickey Trust CR
Footnotes: F1

BRVE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 91,324
Date: 05 Aug 2026
Ownership: By Rickey Trust BR
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BRVE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +300,000
Change %
Price: $0.000000^*
Shares after: 300,000
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 300,000
Exercise price: $18.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Footnote F2

1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.